OnKure Therapeutics, Inc. (OKUR)

Market Cap	32.70M
Revenue (ttm)	n/a
Net Income (ttm)	-59.06M
Shares Out	13.51M
EPS (ttm)	-8.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187,737
Open	2.535
Previous Close	2.420
Day's Range	2.450 - 2.560
52-Week Range	1.700 - 19.999
Beta	n/a
Analysts	Strong Buy
Price Target	32.25 (+1,200.4%)
Earnings Date	Aug 14, 2025

About OKUR

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: OKUR
• Website: https://onkuretherapeutics.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 4 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price forecast is $32.25, which is an increase of 1,200.40% from the latest price.

Price Target

$32.25

(1,200.40% upside)

Analyst Consensus: Strong Buy